Skip to content
PubMed This is a summary of 69 peer-reviewed journal articles Updated

Research & Literature

Explore the leading researchers and institutions driving advances in this area, and dive into the full body of literature that informs this resource.

Explore the Literature Visualize citation networks across 69 referenced papers

Top Authors

Gerd Geerling
Düsseldorf University Hospital
Giuseppe Giannaccare
University of Cagliari
Eli sa beth M. Messmer
Ludwig-Maximilians-Universität München
Flavio Mantelli
Dompé (Italy)
Pedram Hamrah
Tufts University
Francisco C. Figueiredo
Royal Victoria Infirmary
Edward J. Holland
Cincinnati Eye Institute
Christophe Baudouin
Centre National de la Recherche Scientifique
Reza Dana
Massachusetts Eye and Ear Infirmary
Piera Versura
Azienda USL di Bologna

Top Institutions

Ranked by publications Top 10 institutions
04

University of Cagliari

Cagliari, Italy

12 papers
05

Ludwig-Maximilians-Universität München

Munich, Germany

9 papers
Contributors Eli sa beth M. Messmer

References

References (69)
  1. 1

    Synergistic effect of regenerating agent plus cord blood serum eye drops for the treatment of resistant neurotrophic keratitis: a case report and a hypothesis for pathophysiologic mechanism.

    Giannaccare G, Fresina M, Vagge A, Versura P

    International medical case reports journal 2015; (8()):277-81 doi:10.2147/IMCRJ.S89968.

    PMID: 26586967
  2. 2

    [Botulinum toxin A induced protective ptosis for the treatment of recurrent epithelial defects in neurotrophic keratopathy].

    Schilimow A, Wiechens B

    Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2017; (114(8)):745-747 doi:10.1007/s00347-016-0377-7.

    PMID: 27766386
  3. 3

    Corneal Epithelium-Derived Neurotrophic Factors Promote Nerve Regeneration.

    Di G, Qi X, Zhao X, et al.

    Investigative ophthalmology & visual science 2017; (58(11)):4695-4702 doi:10.1167/iovs.16-21372.

    PMID: 28910445
  4. 4

    Neurotrophic factors and corneal nerve regeneration.

    Sacchetti M, Lambiase A

    Neural regeneration research 2017; (12(8)):1220-1224 doi:10.4103/1673-5374.213534.

    PMID: 28966630
  5. 5

    Corneal Neurotization for Neurotrophic Keratopathy: Clinical Outcomes and In Vivo Confocal Microscopic and Histopathological Findings.

    Ting DSJ, Figueiredo GS, Henein C, et al.

    Cornea 2018; (37(5)):641-646 doi:10.1097/ICO.0000000000001522.

    PMID: 29373338
  6. 6

    Phase II Randomized, Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis.

    Bonini S, Lambiase A, Rama P, et al.

    Ophthalmology 2018; (125(9)):1332-1343 doi:10.1016/j.ophtha.2018.02.022.

    PMID: 29653858
  7. 7

    Neurotrophic keratopathy.

    Dua HS, Said DG, Messmer EM, et al.

    Progress in retinal and eye research 2018; (66()):107-131 doi:10.1016/j.preteyeres.2018.04.003.

    PMID: 29698813
  8. 8

    "Therapeutic Penetrating Keratoplasty: A Retrospective Review".

    Roozbahani M, Hammersmith KM, Nagra PK, et al.

    Eye & contact lens 2018; (44 Suppl 2()):S433-S441 doi:10.1097/ICL.0000000000000522.

    PMID: 29944500
  9. 9

    Neurotrophic keratitis: current challenges and future prospects.

    Versura P, Giannaccare G, Pellegrini M, et al.

    Eye and brain 2018; (10()):37-45 doi:10.2147/EB.S117261.

    PMID: 29988739
  10. 10

    Topical insulin in neurotrophic keratopathy after resection of acoustic neuroma.

    Galvis V, Niño CA, Tello A, et al.

    Archivos de la Sociedad Espanola de Oftalmologia 2019; (94(2)):100-104 doi:10.1016/j.oftal.2018.06.003.

    PMID: 30025986
  11. 11

    Clinical Efficacy of Platelet-Rich Plasma in the Treatment of Neurotrophic Corneal Ulcer.

    Wróbel-Dudzińska D, Alio J, Rodriguez A, et al.

    Journal of ophthalmology 2018; (2018()):3538764 doi:10.1155/2018/3538764.

    PMID: 30026985
  12. 12

    Case Series: Management of Neurotrophic Keratitis from Familial Dysautonomia.

    Scanzera AC, Shorter E

    Optometry and vision science : official publication of the American Academy of Optometry 2018; (95(8)):678-681 doi:10.1097/OPX.0000000000001255.

    PMID: 30063663
  13. 13

    Role of corneal nerves in ocular surface homeostasis and disease.

    Labetoulle M, Baudouin C, Calonge M, et al.

    Acta ophthalmologica 2019; (97(2)):137-145 doi:10.1111/aos.13844.

    PMID: 30225941
  14. 14

    [Pathogenesis and epidemiology of neurotrophic keratopathy].

    Mertsch S, Alder J, Dua HS, Geerling G

    Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2019; (116(2)):109-119 doi:10.1007/s00347-018-0823-9.

    PMID: 30478498
  15. 15

    [Clinical picture and diagnosis of neurotrophic keratopathy].

    Messmer EM

    Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2019; (116(2)):120-126 doi:10.1007/s00347-018-0822-x.

    PMID: 30535856
  16. 16

    [Current and experimental treatment approaches for neurotrophic keratopathy].

    Alder J, Mertsch S, Menzel-Severing J, Geerling G

    Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2019; (116(2)):127-137 doi:10.1007/s00347-018-0843-5.

    PMID: 30707284
  17. 17

    Neurotrophic keratopathy: Pros and cons of current treatments.

    Di Zazzo A, Coassin M, Varacalli G, et al.

    The ocular surface 2019; (17(4)):619-623 doi:10.1016/j.jtos.2019.09.002.

    PMID: 31526824
  18. 18

    Corneal Cells: Fine-tuning Nerve Regeneration.

    Kowtharapu BS, Stachs O

    Current eye research 2020; (45(3)):291-302 doi:10.1080/02713683.2019.1675175.

    PMID: 31566418
  19. 19

    Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy: A Multicenter Randomized Vehicle-Controlled Pivotal Trial.

    Pflugfelder SC, Massaro-Giordano M, Perez VL, et al.

    Ophthalmology 2020; (127(1)):14-26 doi:10.1016/j.ophtha.2019.08.020.

    PMID: 31585826
  20. 20

    Neurotrophic keratitis: Frequency, etiologies, clinical management and outcomes.

    Saad S, Abdelmassih Y, Saad R, et al.

    The ocular surface 2020; (18(2)):231-236 doi:10.1016/j.jtos.2019.11.008.

    PMID: 31759182
  21. 21

    Corneal Neurotization: A Review of Pathophysiology and Outcomes.

    Park JK, Charlson ES, Leyngold I, Kossler AL

    Ophthalmic plastic and reconstructive surgery 2020; (36(5)):431-437 doi:10.1097/IOP.0000000000001583.

    PMID: 31923091
  22. 22

    Epithelial Plaque Formation Secondary to Recombinant Human Nerve Growth Factor.

    Weinlander E, Ling J, Reddy A, Nallasamy N

    Cornea 2020; (39(9)):1174-1176 doi:10.1097/ICO.0000000000002300.

    PMID: 32141943
  23. 23

    Amniotic membrane transplantation for managing dry eye and neurotrophic keratitis.

    Mead OG, Tighe S, Tseng SCG

    Taiwan journal of ophthalmology 2020; (10(1)):13-21 doi:10.4103/tjo.tjo_5_20.

    PMID: 32309119
  24. 24

    Direct Versus Indirect Corneal Neurotization for the Treatment of Neurotrophic Keratopathy: A Multicenter Prospective Comparative Study.

    Fogagnolo P, Giannaccare G, Bolognesi F, et al.

    American journal of ophthalmology 2020; (220()):203-214 doi:10.1016/j.ajo.2020.07.003.

    PMID: 32659280
  25. 25

    The molecular basis of neurotrophic keratopathy: Diagnostic and therapeutic implications. A review.

    Ruiz-Lozano RE, Hernandez-Camarena JC, Loya-Garcia D, et al.

    The ocular surface 2021; (19()):224-240 doi:10.1016/j.jtos.2020.09.007.

    PMID: 33022412
  26. 26

    [Cyanoacrylate adhesive in surgrical treatment of corneal perforation (clinical case)].

    Trufanov SV

    Vestnik oftalmologii 2020; (136(5. Vyp. 2)):232-236 doi:10.17116/oftalma2020136052232.

    PMID: 33063970
  27. 27

    On the Horizon: Biologics and Nutrients for Neurotrophic Keratitis.

    Gumus K

    Eye & contact lens 2021; (47(3)):154-156 doi:10.1097/ICL.0000000000000757.

    PMID: 33156130
  28. 28

    Surgical Management of the Ocular Surface in Neurotrophic Keratopathy: Amniotic Membrane, Conjunctival Grafts, Lid Surgery, and Neurotization.

    Trinh T, Mimouni M, Santaella G, et al.

    Eye & contact lens 2021; (47(3)):149-153 doi:10.1097/ICL.0000000000000753.

    PMID: 33196502
  29. 29

    [Consensus of experts on diagnosis and treatment of neurotrophic keratitis in China (2021)].

    [Zhonghua yan ke za zhi] Chinese journal of ophthalmology 2021; (57(2)):90-94 doi:10.3760/cma.j.cn112142-20201028-00715.

    PMID: 33541049
  30. 30

    Neurotrophic Keratopathy: Ophthalmology's Diabetic Foot Problem.

    Margolis TP

    Eye & contact lens 2021; (47(3)):136-139 doi:10.1097/ICL.0000000000000774.

    PMID: 33599469
  31. 31

    Corneal Neurotization in the Setting of Facial Paralysis: A Comprehensive Review of Surgical Techniques.

    Ziai K, Thomas S, Weller C, Lighthall JG

    The Journal of craniofacial surgery 2021; (32(6)):2210-2214 doi:10.1097/SCS.0000000000007590.

    PMID: 33654040
  32. 32

    Neurotrophic keratitis after penetrating keratoplasty for lattice dystrophy.

    Gouvea L, Penatti R, Rocha KM

    American journal of ophthalmology case reports 2021; (22()):101058 doi:10.1016/j.ajoc.2021.101058.

    PMID: 33718661
  33. 33

    Bilateral Severe Corneal Ulcer in a Patient with Lung Adenocarcinoma Treated with Gefitinib.

    Gozzi F, Tiseo M, Facchinetti F, et al.

    Case reports in ophthalmology 2021; (12(1)):288-292 doi:10.1159/000514696.

    PMID: 34054472
  34. 34

    Expert consensus on the identification, diagnosis, and treatment of neurotrophic keratopathy.

    Dana R, Farid M, Gupta PK, et al.

    BMC ophthalmology 2021; (21(1)):327 doi:10.1186/s12886-021-02092-1.

    PMID: 34493256
  35. 35

    Neurotrophic Keratopathy After Herpes Zoster Ophthalmicus.

    Meyer JJ, Liu K, McGhee CNJ, et al.

    Cornea 2022; (41(11)):1433-1436 doi:10.1097/ICO.0000000000003003.

    PMID: 35120347
  36. 36

    Neurotrophic keratopathy: current challenges and future prospects.

    NaPier E, Camacho M, McDevitt TF, Sweeney AR

    Annals of medicine 2022; (54(1)):666-673 doi:10.1080/07853890.2022.2045035.

    PMID: 35243932
  37. 37

    Efficacy of treatments for neurotrophic keratopathy: a systematic review and meta-analysis.

    Roumeau S, Dutheil F, Sapin V, et al.

    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2022; (260(8)):2623-2637 doi:10.1007/s00417-022-05602-z.

    PMID: 35254511
  38. 38

    Management of descemetocele: Our experience and a simplified treatment algorithm.

    Shankar S, Agarwal R, Nagpal R, et al.

    Indian journal of ophthalmology 2022; (70(5)):1564-1570 doi:10.4103/ijo.IJO_3070_21.

    PMID: 35502027
  39. 39

    Characteristics of the ocular surface in neurotrophic keratitis induced by trigeminal nerve injury following neurosurgery.

    Xie C, Liu B, Zhao X, et al.

    International ophthalmology 2023; (43(4)):1229-1240 doi:10.1007/s10792-022-02521-0.

    PMID: 36115903
  40. 40

    Autologous serum eye drops in dry eye disease: Preferred practice pattern guidelines.

    Vazirani J, Sridhar U, Gokhale N, et al.

    Indian journal of ophthalmology 2023; (71(4)):1357-1363 doi:10.4103/IJO.IJO_2756_22.

    PMID: 37026267
  41. 41

    Efficacy of Plasma Rich in Growth Factors (PRGF) in Stage 1 Neurotrophic Keratitis.

    Ghalibafan S, Osei K, Amescua G, Sabater A

    Research square 2023; doi:10.21203/rs.3.rs-3040369/v1.

    PMID: 37461454
  42. 42

    Neurotrophic keratopathy: An updated understanding.

    The ocular surface 2023; (30()):129-138 doi:10.1016/j.jtos.2023.09.001.

    PMID: 37666470
  43. 43

    Neurotrophic keratitis: inflammatory pathogenesis and novel therapies.

    Wajnsztajn D, Faraj LA, Sanchez-Tabernero S, Solomon A

    Current opinion in allergy and clinical immunology 2023; (23(6)):520-528 doi:10.1097/ACI.0000000000000942.

    PMID: 37694830
  44. 44

    Chitosan-based thermosensitive hydrogel with long-term release of murine nerve growth factor for neurotrophic keratopathy.

    Wu J, Huang Y, Yu H, et al.

    Neural regeneration research 2024; (19(3)):680-686 doi:10.4103/1673-5374.380908.

    PMID: 37721301
  45. 45

    Phase IV Multicenter, Prospective, Open-Label Clinical Trial of Cenegermin (rhNGF) for Stage 1 Neurotrophic Keratopathy (DEFENDO).

    Hamrah P, Massaro-Giordano M, Schanzlin D, et al.

    Ophthalmology and therapy 2024; (13(2)):553-570 doi:10.1007/s40123-023-00866-y.

    PMID: 38175466
  46. 46

    Topical application of calcitonin gene-related peptide as a regenerative, antifibrotic, and immunomodulatory therapy for corneal injury.

    Zidan AA, Zhu S, Elbasiony E, et al.

    Communications biology 2024; (7(1)):264 doi:10.1038/s42003-024-05934-y.

    PMID: 38438549
  47. 47

    Substance P promotes transforming growth factor-β-induced collagen synthesis in human corneal fibroblasts.

    Sugioka K, Nishida T, Murakami J, et al.

    American journal of physiology. Cell physiology 2024; (326(5)):C1482-C1493 doi:10.1152/ajpcell.00084.2024.

    PMID: 38525537
  48. 48

    Corneal Neurotization for Neurotrophic Keratopathy: A Multicenter Experience.

    Aujla J, Tong JY, Curragh D, et al.

    Ophthalmic plastic and reconstructive surgery 2024; (40(6)):655-660 doi:10.1097/IOP.0000000000002684.

    PMID: 38624152
  49. 49

    Insights on the Choice and Preparation of the Donor Nerve in Corneal Neurotization for Neurotrophic Keratopathy: A Narrative Review.

    Serra PL, Giannaccare G, Cuccu A, et al.

    Journal of clinical medicine 2024; (13(8)) doi:10.3390/jcm13082268.

    PMID: 38673540
  50. 50

    Corneal Sensitivity Testing Procedure for Ophthalmologic and Optometric Patients.

    Galor A, Lighthizer N

    Journal of visualized experiments : JoVE 2024; doi:10.3791/66597.

    PMID: 39158298
  51. 51

    The THINK Study: Testing Hypoesthesia and the Incidence of Neurotrophic Keratopathy in Cataract Patients with Dry Eye.

    Hovanesian JA

    Clinical ophthalmology (Auckland, N.Z.) 2024; (18()):3627-3633 doi:10.2147/OPTH.S501452.

    PMID: 39659875
  52. 52

    Sandwich Technique and Amniotic Membrane Transplantation as an Effective Method in Repairing Corneal Perforations.

    Ciftci MD, Selver OB

    Middle East African journal of ophthalmology 2023; (30(4)):246-249 doi:10.4103/meajo.meajo_191_23.

    PMID: 39959590
  53. 53

    The Prevalence of Corneal Sensitivity Loss in Patients with and without Dry Eye Disease.

    Stolz M

    Clinical ophthalmology (Auckland, N.Z.) 2025; (19()):1323-1330 doi:10.2147/OPTH.S513005.

    PMID: 40270622
  54. 54

    Corneal Neurotization in Elderly Patients with Multimorbidity.

    Holtmann C, Roth M, Beseoglu K, et al.

    Current eye research 2025; (50(9)):886-893 doi:10.1080/02713683.2025.2509567.

    PMID: 40452082
  55. 55

    The pathogenesis, risk factors, diagnosis and treatment of Acanthamoeba keratitis.

    Bao M, Bao H, Wang S, Zhou H

    Frontiers in medicine 2025; (12()):1559224 doi:10.3389/fmed.2025.1559224.

    PMID: 40776920
  56. 56

    Cenegermin for the Treatment of Moderate or Severe Neurotrophic Keratopathy: Results from a Prospective, Phase IV, Open-Label Study in China.

    Li S, Xu J, Yuan J, et al.

    Ophthalmology and therapy 2025; (14(12)):3021-3033 doi:10.1007/s40123-025-01253-5.

    PMID: 41046317
  57. 57

    Efficacy of Corneal Neurotization Surgery in Eyes With Neurotrophic Keratopathy: A Systematic Review and Meta-Analysis.

    Molinari ME, Huntermann R, Pedrotti Chavez M, et al.

    Annals of plastic surgery 2025; (95(6)):672-679 doi:10.1097/SAP.0000000000004517.

    PMID: 41071907
  58. 58

    Profile and Management Outcomes of Neurotrophic Keratitis at A Tertiary Eye Hospital in Saudi Arabia: A Cohort Study.

    Al Azaz R, Khandekar R, Al Ghadeer H

    Clinical ophthalmology (Auckland, N.Z.) 2025; (19()):3815-3826 doi:10.2147/OPTH.S540546.

    PMID: 41116972
  59. 59

    Beyond the Surface: Revealing the Concealed Effects of Hyperglycemia on Ocular Surface Homeostasis and Dry Eye Disease.

    Zeppieri M, Capobianco M, Visalli F, et al.

    Medicina (Kaunas, Lithuania) 2025; (61(11)) doi:10.3390/medicina61111992.

    PMID: 41303830
  60. 60

    [Recurrence of herpetic eye disease following cataract surgery: risk factors and prevention].

    Mackenbrock LHB, Xu ATL, Naujokaitis T, Khoramnia R

    Die Ophthalmologie 2026; (123(5)):353-358 doi:10.1007/s00347-026-02411-1.

    PMID: 41805863
  61. 61

    Concomitant Tarsorrhaphy During Penetrating Keratoplasty for Promoting Epithelial Healing in Neurotrophic Keratopathy.

    Huang RS, Agarwal M, Mimouni M, Chan CC

    American journal of ophthalmology 2026; (287()):101-108 doi:10.1016/j.ajo.2026.03.027.

    PMID: 41887389
  62. 62

    Subclinical Corneal Neuropathy in Dry Eye Disease: A Driver of Ocular Surface Dysfunction?

    Almaoui E, Calkins DJ, Wareham LK

    Current eye research 2026; (51(9)):1044-1055 doi:10.1080/02713683.2026.2664593.

    PMID: 42080236
  63. 63

    Neurotrophic Keratopathy: Current Concepts, Management, and Emerging Treatments.

    Cheung AY, Holland EJ

    Cornea 2026; (45(6)):673-685 doi:10.1097/ICO.0000000000004055.

    PMID: 42085714
  64. 64

    Retrospective Evaluation of Successive Biovance Decellularized Basement Membrane Tissue Grafts for the Management of Chronic Subclinical and Stage 1 Neurotrophic Keratitis.

    Ayres BD, Fram NR, Wu HK, et al.

    Clinical ophthalmology (Auckland, N.Z.) 2026; (20()):599498 doi:10.2147/OPTH.S599498.

    PMID: 42199330
  65. 65

    Acute Calcific Band Keratopathy After Cenegermin Treatment for Neurotrophic Keratitis.

    Morcos DM, Carbonell BA, Rao N, et al.

    Cornea 2026; doi:10.1097/ICO.0000000000004192.

    PMID: 42228417
  66. 66

    [Corneal melting under PD-1/PD-L1 inhibition].

    Jacobi LF, Thaler S, Bodenbender JP

    Die Ophthalmologie 2026; (123(7)):549-552 doi:10.1007/s00347-026-02458-0.

    PMID: 42268289
  67. 67

    The neuro-immune-epithelial axis in dry eye: From pathogenic crosstalk to neuromodulatory therapies.

    Zhang J, Li Z

    Experimental eye research 2026; (270()):111133 doi:10.1016/j.exer.2026.111133.

    PMID: 42320871
  68. 68

    Therapeutic efficacy of cenegermin in the management of neurotrophic keratitis: a systematic review and meta-analysis of randomized controlled trials.

    Faroog Z, Zaidi ARZ, Tejani S

    Therapeutic advances in ophthalmology 2026; (18()):25158414261460347 doi:10.1177/25158414261460347.

    PMID: 42368179
  69. 69

    Making Corneal Sensation Testing Accessible: Bench Validation of a Low-Cost Adjustable Monofilament Aesthesiometer.

    Maskill D

    Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) 2026; (46(5)):1196-1201 doi:10.1007/s44402-026-00160-x.

    PMID: 42536268